Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07536789) titled 'Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma' on April 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Hepato Cellular Carcinoma (HCC)
Intervention:
Drug: MRG003
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 15, 2026
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07536789
Published by HT Digital Content Ser...